Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
March 28 2024 - 7:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of a new
Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to
enable researchers to detect a more complete view of genetic
variation during whole exome sequencing (WES).
“No one single human genome can serve as a reference
representing everyone. In order to advance science for all people,
researchers need to have tools that enable them to conduct research
relevant to people from diverse backgrounds,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By
leveraging the reference sequences assembled by the Human Pangenome
Reference Consortium, we can offer our customers a tool that can
enable them to better understand the true breadth of human genetic
variation as they develop new assays.”
The Human Pangenome Reference Consortium (HPRC) is a project
funded by the National Human Genome Research Institute (NHGRI) that
has the objective to sequence and assemble complete
telomere-to-telomere genomes from individuals from diverse
populations into a new type of reference in order to better
represent the genomic landscape of diverse human populations. The
updated HPRC reference standard includes samples from 24% African
ancestry, 30% Americas, 18% East Asia and 28% South Asia.
“When companies such as Twist utilize our reference standard to
create research tools, it facilitates scientists’ study of genetic
variation. This may enable the creation of effective diagnostic
tests and treatments for ancestrally diverse genomic data,” said
Bob Fulton and Karen Miga, Co-Chairs of the Production and
Technology Working Group of the Human Pangenome Reference
Project.
The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of
pangenome variants and can be spiked into the Twist Exome 2.0 to
target more than 94% of the novel pangenome variants affecting
coding sequences in the exome.
If interested in the Human Pangenome Spike-in Panel for the
Twist Exome 2.0 panel, please complete the contact form here:
https://www.twistbioscience.com/contact
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the ability of the Human
Pangenome Spike-in Panel for the Twist Exome 2.0 panel to enable
researchers to detect a more complete view of genetic variation
during WES. Forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability in any given period; risks
and uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on February
2, 2024 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328197644/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Generalist
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Sep 2023 to Sep 2024